

Andrea Ferrari

10 pubblicazioni

1. **Ferrari A**, R.Miceli, C.Meazza, M.Casanova, F.Favini, C.Morosi, G.Trecate, A.Marchianò, R.Luksch, G.Cefalo, M.Terenziani, F.Spreafico, D.Polastri, M.Podda, S.Catania, E.Schiavello, P.Giannatempo, L.Gandola, M.Massimino, L.Mariani. Comparison of the prognostic value of assessing tumor diameter versus tumor volume, at diagnosis or in response to initial chemotherapy, in rhabdomyosarcoma. *J Clin Oncol*, 28(8):1322-8, 2010.
2. **Ferrari A**, D.Thomas, A.Franklin, B.Hayes-Lattin, M.Mascarin, W.van der Graaf, K.Albritton. Starting an AYA program: some success stories and some obstacles to overcome. *J Clin Oncol* 28(32):4850-7, 2010
3. **Ferrari A**, Veneroni L, Clerici CA, Casanova M, Chiaravalli S, Magni C, Luksch R, Terenziani M, Spreafico F, Polastri D, Meazza C, Catania S, Schiavello E, Biassoni V, Podda M, Bergamaschi L, Puma N, Moscheo C, Gotti G, Massimino M. Clouds of Oxygen: adolescents with cancer tell their story in music. *J Clin Oncol* 33(2):218-221, 2015
4. **Ferrari A**, De Salvo GL, Brennan B, van Noessel MM, De Paoli A, Casanova M, Francotte N, Kelsey A, Alaggio R, Oberlin O, Carli M, Ben-Arush M, Bergeron C, Merks JHM, Jenney M, Stevens MC, Bisogno G, Orbach D. Synovial sarcoma in children and adolescents: the European pediatric Soft tissue sarcoma Study Group prospective trial (EpSSG NRSTS 2005). *Ann Oncol* 26(3):567-72, 2015
5. van der Graaf W, Orbach D, Judson J, **Ferrari A**. Challenges to improve existing survival gaps for soft tissue sarcomas of adolescents and young adults. *Lancet Oncol* 18:e166–75,2017.
6. **Ferrari A**, Gaggiotti P, Silva M, Veneroni L, Magni C, Signoroni S, Casanova M, Luksch R, Terenziani M, Spreafico F, Meazza C, Clerici CA, Massimino M. In search for happiness. *J Clin Oncol* 35(19):2209-2212, 2017.
7. **Ferrari A**, Brecht IB, Gatta G, Schneider DT, Orbach D, Cecchetto G, Godzinski J, Reguerre Y, Bien E, Stachowicz-Stencel T, Ost M, Magni C, Kearns P, Vassal G, Massimino M, Biondi A, Bisogno G, Trama A. Defining and listing very rare cancers of pediatric age: consensus of the Joint Action on Rare Cancers (JARC) in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors (EXPERT). *Eur J Cancer*, 2019 Mar;110:120-126.
8. Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, **Ferrari A**. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2019 Nov;20(11):1566-1575.
9. Pagani Bagliacca E, Silva M, Veneroni L, Casanova M, Gasparini P, Signoroni S, Massimino M, **Ferrari A**. YOUTH: the sweatshirt collection created by adolescent cancer patients on the Youth Project in Milan. *Lancet Oncol*. 2020 Mar;21(3):341-342..
10. **Ferrari A**, Merks JHM, Chisholm JC, Orbach D, Brennan B, Gallego S, van Noesel MM, McHugh K, van Rijn RR, Gaze MN, Martelli H, Bergeron C, Corradini N, Minard-Colin V, Bisogno G, Georger B, Caron HN, De Salvo GL, Casanova M. Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. *Eur J Cancer*. 2020 2020 May;130:72-80.